(Q40489054)

English

Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Robert M Rifkin

1

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Stephanie A Gregory

2

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Ann Mohrbacher

3

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Mohamad A Hussein

4

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

language of work or name

0 references

publication date

1 February 2006

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

106

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

848-858

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21662

21 January 2018

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21662

7 January 2021

based on heuristic

inferred from DOI database lookup

Modifications to therapy for multiple myeloma: pegylated liposomal Doxorubicin in combination with vincristine, reduced-dose dexamethasone, and thalidomide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21662

7 January 2021

based on heuristic

inferred from DOI database lookup

Effective treatment of advanced multiple myeloma refractory to alkylating agents.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21662

7 January 2021

based on heuristic

inferred from DOI database lookup

VAD-based regimens as primary treatment for multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21662

7 January 2021

based on heuristic

inferred from DOI database lookup

Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21662

7 January 2021

based on heuristic

inferred from DOI database lookup

Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21662

7 January 2021

based on heuristic

inferred from DOI database lookup

VAD chemotherapy for refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21662

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21662

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose therapy in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21662

7 January 2021

based on heuristic

inferred from DOI database lookup

The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21662

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21662

7 January 2021

based on heuristic

inferred from DOI database lookup

Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21662

7 January 2021

based on heuristic

inferred from DOI database lookup

A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21662

7 January 2021

based on heuristic

inferred from DOI database lookup

Single agent vincristine by infusion in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21662

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21662

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21662

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21662

7 January 2021

based on heuristic

inferred from DOI database lookup

No correlation between response and survival in patients with multiple myeloma treated with vincristine, melphalan, cyclophosphamide, and prednisone

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21662

7 January 2021

based on heuristic

inferred from DOI database lookup

Single versus double autologous stem-cell transplantation for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21662

7 January 2021

based on heuristic

inferred from DOI database lookup

Administration of a modified chemotherapeutic regimen containing vincristine, liposomal doxorubicin and dexamethasone to multiple myeloma patients: preliminary data

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21662

7 January 2021

based on heuristic

inferred from DOI database lookup

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21662

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21662

7 January 2021

based on heuristic

inferred from DOI database lookup

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21662

7 January 2021

based on heuristic

inferred from DOI database lookup

Synergy between all-trans retinoic acid and tumor necrosis factor pathways in acute leukemia cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21662

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.21662

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40489054&oldid=1531108578"